Loading...
Indian Pharmaceutical Exporter · #8 for Artemether · $9.1M export value · DGFT Verified
S K AGE Exports is the #8 Indian exporter of Artemether with $9.1M in export value and 237 verified shipments. S K AGE Exports holds a 1.0% market share in Artemether exports across 16 countries. The company exports 9 pharmaceutical products worth $25.0M across 5 therapeutic categories.
| $673.6K |
| 19 |
| 5.2% |
| BURKINA FASO | $397.8K | 10 | 3.1% |
| GHANA | $364.7K | 33 | 2.8% |
| NIGERIA | $350.0K | 7 | 2.7% |
| MOZAMBIQUE | $258.4K | 10 | 2.0% |
| MALAWI | $250.3K | 6 | 1.9% |
S K AGE Exports exports Artemether to 22 countries. The largest destination is TANZANIA accounting for 33.6% of S K AGE Exports's Artemether shipments, followed by UGANDA (22.3%) and ANGOLA (9.8%). These destinations reflect S K AGE Exports's established distribution network and regulatory approvals in key markets.
| Buyer | Country | Value | Orders |
|---|---|---|---|
| TO THE ORDER | UGANDA | $11.2M | 399 |
| ERRA | UGANDA | $486.6K | 12 |
| TO THE ORDER. | BURKINA FASO | $123.2K | 4 |
S K AGE Exports supplies Artemether to 3 buyers globally. The largest buyer is TO THE ORDER (UGANDA), followed by ERRA (UGANDA) and TO THE ORDER. (BURKINA FASO). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
India exported $155.1M worth of Artemether through 8,652 shipments from 481 suppliers to 107 countries, serving 1,561 buyers globally. S K AGE Exports contributes $9.1M to this total, accounting for 1.0% of India's Artemether exports. S K AGE Exports ships Artemether to 22 countries through 3 buyers.
S K AGE Exports's average Artemether shipment value is $38.2K per consignment, based on 237 shipments totaling $9.1M. The largest destination is TANZANIA (33.6% of S K AGE Exports's Artemether exports).
S K AGE Exports ranks #8 among 481 Indian Artemether exporters with a 1.0% market share. The top 3 exporters are IPCA LABORATORIES LIMITED ($30.0M), MACLEODS PHARMACEUTICALS LTD ($25.5M), INNOVA CAPTAB LIMITED ($16.2M). S K AGE Exports processed 237 shipments to 16 destination countries.
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| HARMLESS MEDICINE-ARTEMETHER 20MG + LUME | $1.7M | 48 |
| HARMLESS MEDICINES-ARTEMETHER 20MG + LUM | $602.9K | 14 |
| HARMLESS MEDICINES - ARTEMETHER 20MG + LUMEFANTRINE 120MG TABLETS U/C (LARTEM) Unit : 24 Tab | $600.0K | 12 |
| HARMLESS MEDICINES- ARTEMETHER 20MG + LUMEFANTRINE 120MG TABLETS U/C (LARTEM) Unit : 24 Tab | $590.5K | 13 |
| HARMLESS MEDICINE - ARTEMETHER 20MG + LUMEFANTRINE 120MG TABLETS U/C (LARTEM) Unit : 24 Tab | $576.5K | 13 |
| ARTEMETHER 20MG + LUMEFANTRINE 120MG TAB | $575.7K | 26 |
| HARMLESS MEDICINE-ARTEMETHER 20MG + LUMEFANTRINE 120MG TABLETS U/C LARTEM UNIT:24 TAB | $552.8K | 12 |
| HARMLESS MEDICINE-ARTEMETHER 20MG + LUMEFANTRINE 120MG TABLETS U/C (LARTEM) UNIT:24 TABNOS | $534.1K | 18 |
| HARMLESS MEDICINES- ARTEMETHER 20MG + LUMEFANTRINE 120MG TABLETS U/C (LARTEM) UNIT:24 TAB | $503.1K | 16 |
| HARMLESS MEDICINES-ARTEMETHER 20 MG + LU | $379.1K | 11 |
S K AGE Exports exports 138 distinct Artemether formulations including tablets, capsules, syrups, and combination drugs. The top formulation is HARMLESS MEDICINE-ARTEMETHER 20MG + LUME with 48 shipments worth $1.7M. Notable combination products include fixed-dose combinations with other active ingredients, meeting diverse global regulatory requirements.
Exporters ranked immediately above and below #8 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 3 | INNOVA CAPTAB LIMITED | $16.2M | 324 | 5 | $50.0K |
| 7 | AJANTA PHARMA LIMITED | $15.1M | 391 | 27 | $38.7K |
| 8 | S K AGE EXPORTS ★ | $9.1M | 237 | 16 | $38.2K |
| 6 | AFROWAY PHARMA | $8.6M | 171 | 3 | $50.0K |
| 9 | S KANT HEALTHCARE LIMITED | $8.4M | 191 | 9 | $44.1K |
S K AGE Exports ranks #8 among 481 Indian Artemether exporters. Average shipment value of $38.2K compared to the market average of $322.4K. The closest competitors by value are INNOVA CAPTAB LIMITED and AJANTA PHARMA LIMITED.
| Port | Shipments | % Share |
|---|---|---|
| NHAVA SHEVA SEA (INNSA1) | 1,326 | 15.3% |
| JNPT/ NHAVA SHEVA SEA | 817 | 9.4% |
| JNPT | 788 | 9.1% |
| SAHAR AIR | 757 | 8.7% |
| SAHAR AIR CARGO ACC (INBOM4) | 622 | 7.2% |
| AHEMDABAD ICD | 420 | 4.9% |
| NHAVA SHEVA SEA | 272 | 3.1% |
| MUNDRA SEA | 269 | 3.1% |
S K AGE Exports also exports these antimalarial & antiparasitic products. Each links to the detailed product page.
The current geopolitical landscape presents both challenges and opportunities for Indian pharmaceutical exporters like S K AGE Exports. The Israel-Iran conflict has led to disruptions in Red Sea shipping routes, causing increased shipping costs and extended transit times. These disruptions have resulted in freight inflation, with transport charges doubling and surcharges ranging from $4,000 to $8,000 per shipment. (pharmaceuticalcommerce.com) Such logistical challenges can impact the timely delivery of pharmaceuticals, particularly to markets in the Middle East and North Africa.
Conversely, US-China trade tensions have prompted the United States to seek alternative sources for pharmaceuticals, potentially benefiting Indian exporters. India supplies 47% of the US's generic drugs, underscoring its critical role in the American healthcare system. (orfonline.org) However, the imposition of tariffs on Indian pharmaceutical products by the US poses a risk, potentially leading to reduced export volumes and increased compliance costs. (transdatanexus.com)
In the European Union, the implementation of the Falsified Medicines Directive (FMD) necessitates stringent compliance measures. Indian exporters must ensure adherence to these regulations to maintain market access. The India–EFTA Trade and Economic Partnership Agreement, effective from October 1, 2025, aims to eliminate or reduce tariffs on goods traded between India and EFTA countries, potentially enhancing market opportunities for exporters like S K AGE Exports. (en.wikipedia.org)
Compliance with international regulatory standards is paramount for Indian pharmaceutical exporters. India has made significant strides in this area, with 752 FDA-approved, 2,050 WHO GMP-certified, and 286 EDQM-approved manufacturing facilities as of 2024. (ibef.org) Instances of non-compliance have decreased, indicating improved adherence to quality standards. For S K AGE Exports, maintaining such compliance is essential to ensure uninterrupted market access and to uphold the company's reputation in the global pharmaceutical industry.
S K AGE Exports exports 9 products worth $25.0M. Beyond Artemether, top products include Clotrimazole, Gentamicin, Erythromycin, Sulfadoxine, Pyrimethamine. View the complete S K AGE Exports profile for full portfolio analysis.
Latest developments and market context
Detailed market intelligence for Artemether — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Verify manufacturer licensing and export certifications with the official agencies above.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 107+ countries, 1,561+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Access shipment-level details, pricing data, buyer connections, and competitive analysis for S K AGE Exports's Artemether exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
S K AGE Exports
Full Company Profile →
9 products · $25.0M total trade · 5 categories
Access shipment-level records, pricing trends, and buyer contacts for S K AGE Exports.
Request DemoView Pricing →Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Artemether. For current shipment-level data, contact TransData Nexus.